We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Point-Of-Care HbA1c Analyzer Enhanced

By LabMedica International staff writers
Posted on 29 Mar 2011
A point-of-care (POC) immunoassay analyzer for diabetes management provides enhanced operator management and connectivity capabilities to meet the growing demands in POC testing for improved compliance management and data capture into patient records.

The DCA Vantage Analyzer ensures that all analyzers are running the same quality control regimen required by their institution and that only authorized operators are running the devices according to their specified access level.

The operator management capability has been expanded to support up to 1,000 operators, each with their unique access level as defined by their supervisor. More...
Another enhancement to the analyzer is the ability to display, print, and transmit the HbA1c reference ranges with the patient results, aiding in improved results interpretation.

POC managers are demanding better connectivity between their POC analyzers and the associated healthcare organization so that test results can be automatically transmitted to the laboratory and hospital information systems, and eventually to the patient's electronic medical record.

Siemens Healthcare Diagnostics (Erlangen, Germany) launched the DCA Vantage Analyzer with Version 3.0 software. It has the capacity to manage a larger number of operators while providing the required security access modes to prevent unauthorized use. In addition, the analyzer is one of the first hemoglobin A1c (HbA1c) POC analyzers in the industry to include the POCT1-A2 communication protocol. Use of this standard interface simplifies the connection to POC data management systems, enabling results to be automatically transmitted to the patient electronic medical record.

"We are focused on providing our customers with a trusted, clinically proven, point-of-care analyzer to better manage diabetes patients at the time of visit," said Dr. David Stein, CEO, POC business unit, Siemens Healthcare Diagnostics. "At the same time, we are continually looking at ways to enhance our products to meet the changing needs of our customers. These newly added features are important to point-of-care managers who are responsible for tests conducted at remote sites with multiple operators and devices in order to drive testing compliance."

Related Links:

Siemens Healthcare Diagnostics



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.